Scope
The AHA scientific statement addresses prevention of viridans group streptococcal infective endocarditis, with emphasis on selective dental antibiotic prophylaxis and ongoing oral health. This summary covers the society’s published highlights; it is not a prescription guide or a complete list of qualifying cardiac conditions.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Select patients and procedures carefully
- For dental procedures involving gingival manipulation, the tooth periapical region, or perforation of oral mucosa, reserve consideration of antibiotic prophylaxis for patients at the highest risk of a poor outcome from viridans streptococcal endocarditis. [1]
- Do not use increased lifetime susceptibility to viridans streptococcal endocarditis alone as the reason for dental antibiotic prophylaxis. The decision concerns the risk of an adverse outcome, not lifetime acquisition risk alone. [1]
- Explain the small potential population benefit of dental prophylaxis: even perfectly effective prophylaxis could prevent only a very small number of viridans streptococcal endocarditis cases. [1]
Prioritise ongoing oral health and access
- Make good oral health and regular dental care central to prevention. The statement gives these measures greater preventive importance than antibiotics before a dental procedure. [1]
- Explain that ordinary daily activities causing transient oral bacteraemia are a more likely source of viridans streptococcal endocarditis than an individual dental procedure. This supports sustained oral care rather than focusing prevention solely on procedure days. [1]
- Where affordability or coverage restricts dental access, connect patients to social work or other assistance. This is particularly relevant for people at greatest risk of severe consequences from endocarditis. [1]
Limitations and use
- This focused summary does not give the complete list of qualifying cardiac conditions, antibiotic selection, doses or contraindications. It must not be used alone to decide eligibility or prescribe dental prophylaxis.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Prevention of viridans group streptococcal infective endocarditis — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AHA
- First published
- 15 April 2021
- Resource type
- Scientific statement · House clinical summary
Earlier House summaries: infective endocarditis prevention aha
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.